Nuvalent Inc (NUVL)
69.25
-1.10
(-1.56%)
USD |
NASDAQ |
May 06, 16:00
69.25
0.00 (0.00%)
After-Hours: 20:00
Nuvalent Cash from Financing (TTM): 336.85M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 336.85M |
September 30, 2023 | 252.10M |
June 30, 2023 | 250.96M |
March 31, 2023 | 249.67M |
December 31, 2022 | 248.92M |
September 30, 2022 | -0.701M |
June 30, 2022 | 173.23M |
Date | Value |
---|---|
March 31, 2022 | 307.45M |
December 31, 2021 | 318.22M |
September 30, 2021 | 319.18M |
June 30, 2021 | 154.25M |
March 31, 2021 | 19.76M |
December 31, 2020 | 22.26M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.701M
Minimum
Sep 2022
336.85M
Maximum
Dec 2023
204.01M
Average
249.67M
Median
Mar 2023
Cash from Financing (TTM) Benchmarks
Geron Corp | 228.77M |
Verastem Inc | 134.19M |
Karyopharm Therapeutics Inc | 1.124M |
Syndax Pharmaceuticals Inc | 264.13M |
AnaptysBio Inc | -59.30M |